MedinCell proposes a long-acting solution to malaria transmission and collaborates with the Medicines Patent Pool
1 April 2020
Geneva, 31 March 2020 – The Medicines Patent Pool (MPP) congratulates MedinCell on receiving a Unitaid grant to lead revolutionary long-acting medicines research in the fight against malaria. The IMPACT project seeks to develop a long-acting injectable form of ivermectin that would be easier to administer and adhere to. A long-acting injectable version of ivermectin could make an important contribution to the global goal of ending malaria as an epidemic by 2030.
MPP is proud to partner with all three of Unitaid’s long-acting projects, MedinCell, University of Liverpool and the University of Washington to step up the fight against Malaria, HIV, HepC and TB. MPP will leverage its expertise and model to address access barriers early in the development cycle and, to provide a pathway for low- and middle-income countries to promptly obtain these new products. With its recognised expertise in intellectual property-related facilitation, MPP will engage with the different stakeholders to secure partners in accelerating access to affordable quality revolutionary long-acting treatments in the countries where they are needed.
More:
- Read MPP’s statement on University of Liverpool and University of Washington forging the way in revolutionary long-acting medicines.
- Read MPP and Unitaid’s joint intellectual property report on long-acting technologies
